CA
NZ
UK
AU
IND
US
Jupiter Neurosciences (NASDAQ: JUNS) sold 11,470,000 common shares for about $3.6 million, pricing each at 97% of the three‑day VWAP. The transaction occurs as the stock trades at $0.10, with a market capitalisation of $8 million. The cash infusion provides immediate funding, yet the …
Parallel has suspended operations at two of its facilities, resulting in a significant reduction of its workforce by 211 employees. The closures primarily affect its Wimauma and Lakeland sites in Florida, where various production and cultivation roles have been eliminated. Employees affected by these …
Revenue in the period measured $865.8 million, essentially unchanged from the prior year after normalizing for supplemental payment timing, while same‑facility patient days nudged up 0.8% and revenue per patient day fell 0.8%.
American Shared Hospital Services (NYSE American: AMS) entered a third amendment to its credit agreement that extends a lender forbearance to June 30 2027 and removes the Minimum Unrestricted Cash and Fixed Charge Coverage covenants for the same period. The amendment also blocks new …
Boston Scientific Corp. is launching a comprehensive global restructuring program with costs projected between $700 million and $800 million, reflecting its strategic focus on driving long-term growth and cost efficiencies. This initiative encompasses significant headcount reductions and supply chain optimizations aimed at aligning its …
Grace Therapeutics (NASDAQ: GRCE) has received meeting minutes from the FDA regarding its GTx-104 NDA, highlighting necessary steps for resubmission. Despite this clarity, the stock has declined 40.4% year-to-date, revealing significant investor caution amid ongoing regulatory scrutiny.Key HighlightsThe company’s market capitalization stands at approximately …
Johnson & Johnson's recent resolution of its talc litigation strengthens its stock's appeal, shedding liabilities that have weighed on investor confidence. The market is responding favorably, indicating renewed interest in the company amid broad shifts away from technology-driven trades.Key HighlightsJohnson & Johnson settled its …
NeuroPace (NASDAQ: NPCE) received an FDA notice that its supplemental pre‑market approval for expanding the RNS System into drug‑resistant idiopathic generalized epilepsy is not approvable in its current form, prompting a request for additional clinical evidence. The agency’s feedback centers on the need for …
Novocure (NASDAQ: NVCR) shares closed up 28% at $19.99 after the company reported Q2 2026 net revenue of $183.58 million, up 16% year-over-year and beating the $172.44 million consensus estimate, in one of the sharpest single-day rallies among biopharma names this session.
KALA BIO, Inc. (NASDAQ: KALA) shares closed down 17% at $0.61 after the company submitted a prospectus supplement for an at-the-market equity offering to potentially sell as much as $250 million in common stock.
Please wait processing your request...